Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).
Niederwieser C, Iacobelli S, Franke GN, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller LP, Stelljes M, Morozova E, Passweg J, Onida F, Dreger P, Saccardi R, Ladetto M, Salmenniemi U, Bethge W, Poiré X, Kobbe G, McLornan DP, Robin M, Kröger N.
Niederwieser C, et al. Among authors: hubel k.
Bone Marrow Transplant. 2024 Aug;59(8):1084-1091. doi: 10.1038/s41409-024-02282-7. Epub 2024 Apr 25.
Bone Marrow Transplant. 2024.
PMID: 38664589
Free PMC article.
Clinical Trial.